Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol

Sara Harsini, Maryam Soleimani, Don Wilson, Carlos Uribe, Heather Saprunoff, Ingrid Bloise and Francois Benard
Journal of Nuclear Medicine April 2025, jnumed.124.269064; DOI: https://doi.org/10.2967/jnumed.124.269064
Sara Harsini
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maryam Soleimani
2Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don Wilson
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Uribe
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
3Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Saprunoff
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Bloise
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Benard
1Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada;
3Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol
Sara Harsini, Maryam Soleimani, Don Wilson, Carlos Uribe, Heather Saprunoff, Ingrid Bloise, Francois Benard
Journal of Nuclear Medicine Apr 2025, jnumed.124.269064; DOI: 10.2967/jnumed.124.269064

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol
Sara Harsini, Maryam Soleimani, Don Wilson, Carlos Uribe, Heather Saprunoff, Ingrid Bloise, Francois Benard
Journal of Nuclear Medicine Apr 2025, jnumed.124.269064; DOI: 10.2967/jnumed.124.269064
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

Keywords

  • prostate cancer
  • theranostics
  • PSMA
  • metastatic castration-resistant prostate cancer
  • radiopharmaceutical therapy
SNMMI

© 2025 SNMMI

Powered by HighWire